(STEP 1, NEJM , 2021) reported a mean 14.9% body-weight reduction at 68 weeks with once-weekly 2.4 mg semaglutide in adults with obesity, anchoring the clinical weight-management literature [1]
Yes, we only treat patients 24 and older
There is no live video visit
GLP-1 receptor agonist medications (including semaglutide, dulaglutide, liraglutide, exenatide, and lixisenatide) are typically considered for type 2 diabetes when: Triple therapy with other diabetes medications is not effective, not tolerated, or contraindicated The person has a BMI 35 kg/m (adjusted by 2.5 kg/m for people from South Asian, Chinese, other Asian, Black African, or African-Caribbean backgrounds) and specific weight-related psychological or medical problems A lower BMI threshold may be appropriate if weight loss would benefit other obesity-related comorbidities Insulin would not be appropriate or acceptable to the person Treatment is usually continued only if there is a beneficial metabolic response (reduction in HbA1c and weight) after 6 months
Im not a fan of the frequent dosing schedule, but the results are noticeable after about two weeks
Whether you are evaluating a licensing opportunity, preparing a portfolio review, or building conviction on a competitive position, K-Dense Web cuts the timeline from weeks to hours
